Drug-Induced Immune Thrombocytopenic Purpura Secondary to Sunitinib

M. Trinkaus; M. Trudeau; J. Callum

doi:10.3747/co.v15i3.233

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Article

1 June 2008

Drug-Induced Immune Thrombocytopenic Purpura Secondary to Sunitinib

and

Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada

Department of Hematology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada

Author to whom correspondence should be addressed.

Curr. Oncol.2008, 15(3), 152-154;https://doi.org/10.3747/co.v15i3.233

Version Notes

Order Reprints

Abstract

Sunitinib (Sutent: Pfizer, New York, NY, U.S.A.) is an oral multi-targeted tyrosine kinase inhibitor approved for use in various solid tumour malignancies. Many side effects secondary to sunitinib have been documented. In particular, sunitinib administration is known to result in thrombocytopenia, with the cause being attributed to myelosuppression. Here, we present the first case report to demonstrate immune-mediated thrombocytopenia secondary to sunitinib administration.

Keywords:

breast cancer; thrombocytopenia; sunitinib

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Single versus Multiple Fractions of Palliative Radiotherapy for Bone Metastases: A Randomized Clinical Trial in Iranian Patients

The 3rd Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake